Suggestions
Maulik Majmudar, M.D.
Chief Medical Officer and Co-Founder at Biofourmis
Dr. Maulik Majmudar is a prominent cardiologist and the Chief Medical Officer and Co-Founder of Biofourmis, a company specializing in virtual care delivery and digital therapeutics. His role at Biofourmis began in April 2021, where he has been instrumental in advancing health technology solutions aimed at improving patient outcomes.
Educational Background and Early Career:: Dr. Majmudar earned his M.D. from Northwestern University Feinberg School of Medicine. He completed his residency in Internal Medicine at The Johns Hopkins Hospital and subsequently undertook a fellowship in cardiovascular medicine at Brigham and Women’s Hospital. His academic contributions include serving as an Assistant Professor at Harvard Medical School and as a lecturer at MIT, where he focused on healthcare innovation.
Professional Experience:: Before co-founding Biofourmis, Dr. Majmudar held several significant positions:
- Medical Officer at Amazon (2018-2021): He was pivotal in the development of Amazon Halo, a health and wellness service.
- Associate Director at Massachusetts General Hospital’s Healthcare Transformation Lab (2013-2018): Here, he worked on implementing digital health solutions to enhance care delivery.
- Founding Member and Chief Clinical Officer at Quanttus (2012-2016): He contributed to the development of innovative health technologies.
Dr. Majmudar has also been involved in research, holding two patents and publishing in notable journals such as Nature and JAMA. His work has been recognized with an education grant from the Aetna Foundation to foster innovation in healthcare through a new fellowship program.
Overall, Dr. Majmudar's extensive background in cardiology, digital health, and innovation positions him as a leader in transforming healthcare delivery through technology.
Highlights
Really excited to try out the OTC #stelo from Dexcom for glucose monitoring! With a family history of diabetes and being a strict vegetarian (and having a sweet tooth), I have always been curious about my glucotype and my glycemic responses to various diets and specifically, South Asian foods. And now I can! Without any prescriptions and with high fidelity measurements. Eric Topol, MD Michael Snyder Nikhil Krishnan Fatima Cody Stanford Vinod Khosla
We need a better approach that leverages different data types and validated diagnostic imaging approaches for a more precise risk estimation. On one hand, there are patients who are not on any lipid-lowering therapies at the time of their first major cardiovascular event due to underestimation of risk. On the other hand, NNT is still way too high for these models: ASCVD or PREVENT. Robert A. Harrington Eric Topol, MD Peter Attia Khurram Nasir, MD MPH MSc Arjun Manrai Isaac Kohane
